Chemobrain ... Is It Real?

Cancer Newsline - 09/20/2010

Chemobrain, or difficulty in efficiently processing information, is a legitimate, diagnosable condition that may be caused by chemotherapy treatment, the cancer itself, or secondary medical conditions such as anemia. Christina Meyers, Ph.D., Professor of Neuro-Oncology at MD Anderson Cancer Center, discusses chemobrain and how it can affect cancer patients.

Guest(s): Christina Meyers, Ph.D.

• Listen to Chemobrain ... Is It Real?
• Download Chemobrain ... Is It Real? on iTunes

U.S. webinar Oct 7th - Upcoming Webinar: Pre-Existing Condition Insurance Plans Created by the Affordable Care Act - The Commonwealth Fund

The Commonwealth Fund invites you to join a free webinar on pre-existing condition insurance plans, part of a series of webinars on realizing health reform's potential. This one-hour webinar, to be held Thursday, Oct. 7, at 2 p.m., E.T., will address the Affordable Care Act provision on establishing temporary high-risk pools, also called preexisting condition insurance plans (PCIP), which are designed to quickly make health insurance available to uninsured individuals with preexisting conditions, many of whom previously had been denied coverage. Speakers will examine eligibility, benefits, premiums and cost-sharing, enrollment and outreach, and oversight of the PCIP programs, as well as plan variability.

What: 'Realizing Health Reform's Potential' Webinar: Pre-Existing Condition Insurance Plans Created by the Affordable Care Act

When: Thursday, Oct. 7, at 2 p.m., E.T.

Speakers: Jean P. Hall, Ph.D., associate research professor at the University of Kansas and author of a new Commonwealth Fund report on PCIPs, and Amie Goldman, CEO, the Health Insurance Risk-Sharing Plan Authority in Wisconsin and chair of the National Association of State Comprehensive Health Insurance Plans; and Deborah Armstrong, executive director, New Mexico Medical Insurance Pool

Moderator: Sara R. Collins. Ph.D., vice president, Affordable Health Insurance, The Commonwealth Fund

To register, go to: https://cc.readytalk.com/r/8ctspn2599j0

Women's Health Highlights: Recent Findings (numerous topics including ovarian cancer)

Herbs and Supplements: special section MedlinePlus

The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer

Conclusions

Although elderly patients appear to tolerate fewer cycles of IP chemotherapy, they do not have higher objective complication rates or impaired PFS compared to younger patients. Age alone should not limit access to IP chemotherapy.